Table 1 Patient characteristics.

Patient^a	PS	HLA-A type	Peptide	Prior therapy	ELISPOT (CTL)			CTL induction
Patient^a	PS	HLA-A type	Peptide	Prior therapy	Mo	R1	R2	R1	R2
Case 1	3	2402/3303	2402	Surgery (bil. ves. sch), Rad (bil. ves. sch)	0	1+	–	+	+
					3	NT	NT
					6	3+	3+
Case 2	1	2402/3101	2402	Surgery (bil. ves. sch), Rad (Lt. ves. sch)	0	–	–	+	+
					3	–	1+
					6	1+	–
					12	–	3+
Case 3	1	2402/0201	2402	Surgery (bil. ves. sch)	0	–	–	+	+
					3	3+	2+
					6	3+	3+
					12	–	2+
					18	3+	3+
Case 4	1	2402/3101	2402	Surgery (Rt. ves. sch)	0	–	1+	+	+
					3	NT	NT
					6	3+	3+
					12	3+	3+
Case 5	1	0207/0301	0201	Surgery (FB Men)	0	1+	1+	+	–
					3	2+	–
					6	1+	1+
Case 6	1	2402/2420	2402	Surgery (C1), Rad (Lt. ves.sch), Bev^a	0	2+	1+	+	+
					3	3+	2+
					6	1+	1+
Case 7	1	0206/2602	0201	Surgery (Rt. ves. sch)	0	2+	–	+	+
					3	–	3+
					6	3+	–

Bev bevacizumab, bil bilateral, CTL cytotoxic T lymphocyte, ELISPOT enzyme-linked immunospot, F female, FB frontal base, Lt left, M male, Men meningioma, Mo months after the first vaccination, NT not tested, PS performance status, Rad radiosurgery, R1 vascular endothelial growth factor receptor 1, R2 vascular endothelial growth factor receptor 2, Rt right, sch schwannoma, ves vestibular
^aAlthough four cycles of Bev were administered 3 years before the first vaccination, tumor growth was not regulated

Quick links

Search